Brett Tounge

Brett Tounge

Company: Mebias Discovery

Job title: Co-Founder


Developing Highly Signaling-Pathway Selective Molecules Using Mebias’ 19Fluid Platform 2:30 pm

19F NMR of native GPCRs in solution Conformation driven drug discovery to determine pathway selectivity Integrating pathway selectivity into drug discoveryRead more

day: Day One

Panel Discussion: Biased Signaling: From Pharmacology to Physiology 12:00 pm

GPCR signaling can be activated in a ‘biased’ response, via G proteins or β-arrestins with distinct biochemical and physiological actions from each other. The current field however requires further clarity to evaluate biased signaling from pharmacology to physiology for the benefit of discovering biologically relevant GPCR targets. From determining bias specificity to rationally designing biased…Read more

day: Pre Conference Focus Day

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.